Edgewise Therapeutics, Inc. (NASDAQ:EWTX) General Counsel John R. Moore Sells 17,993 Shares of Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Free Report) General Counsel John R. Moore sold 17,993 shares of Edgewise Therapeutics stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $20.00, for a total value of $359,860.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

John R. Moore also recently made the following trade(s):

  • On Friday, February 9th, John R. Moore sold 8,029 shares of Edgewise Therapeutics stock. The shares were sold at an average price of $20.01, for a total value of $160,660.29.
  • On Wednesday, December 27th, John R. Moore sold 8,497 shares of Edgewise Therapeutics stock. The shares were sold at an average price of $10.50, for a total value of $89,218.50.

Edgewise Therapeutics Trading Down 1.7 %

EWTX opened at $19.47 on Friday. Edgewise Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $20.69. The business’s 50-day simple moving average is $11.78 and its 200 day simple moving average is $8.37.

Edgewise Therapeutics (NASDAQ:EWTXGet Free Report) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, research analysts predict that Edgewise Therapeutics, Inc. will post -1.55 earnings per share for the current year.

Institutional Trading of Edgewise Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Trexquant Investment LP acquired a new position in shares of Edgewise Therapeutics in the fourth quarter valued at approximately $608,000. Dimensional Fund Advisors LP grew its position in shares of Edgewise Therapeutics by 49.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 262,238 shares of the company’s stock valued at $2,871,000 after purchasing an additional 87,317 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Edgewise Therapeutics in the fourth quarter valued at approximately $515,000. AJOVista LLC acquired a new position in shares of Edgewise Therapeutics in the fourth quarter valued at approximately $84,000. Finally, Swiss National Bank acquired a new position in shares of Edgewise Therapeutics in the fourth quarter valued at approximately $548,000.

Analyst Ratings Changes

Separately, Wedbush decreased their target price on Edgewise Therapeutics from $27.00 to $23.00 and set an “outperform” rating for the company in a research note on Friday, November 10th.

Read Our Latest Report on Edgewise Therapeutics

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

Featured Articles

Insider Buying and Selling by Quarter for Edgewise Therapeutics (NASDAQ:EWTX)

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.